What is OpAns?
OpAns is a specialized provider of bioanalytical and clinical diagnostics services, renowned for its innovative solutions in areas such as workplace drug testing and justice system applications. The company leverages its patented amasse device, which facilitates efficient micro-sampling for precise testing of steroid hormones, biomarkers, and other critical compounds. Serving a broad spectrum of clients including clinics, healthcare providers, and payors, OpAns focuses on delivering personalized testing strategies and ensuring compliance with industry standards. With a legacy spanning over two decades, OpAns is dedicated to refining analytical methodologies to meet diverse application requirements.
How much funding has OpAns raised?
OpAns has raised a total of $482K across 2 funding rounds:
Debt
$150K
Debt
$332K
Debt (2020): $150K with participation from PPP
Debt (2021): $332K led by PPP
What's next for OpAns?
The recent large-scale, late-stage funding signifies a pivotal moment for OpAns, positioning the company for accelerated growth and market penetration. This strategic capital infusion is expected to fuel further development of its innovative diagnostic technologies and expand its service offerings. OpAns is poised to enhance its competitive edge by scaling operations, potentially exploring new market segments, and solidifying its role as a leader in advanced bioanalytical and clinical diagnostics.
See full OpAns company page
